Company intelligence / Profile preview
BioIntegrate
- Ownership
- Private
- Development stage
- Other
01
Overview
BioIntegrate LLC is developing mesenchymal stem cell therapies, with its lead program in umbilical cord-derived Wharton's Jelly mesenchymal stem cells targeting knee osteoarthritis. The program has reached Phase 2 clinical trials. Early literature suggests promising responses in related indications such as severe ocular involvement during acute epidermal necrolysis and erythema multiforme major, but the main focus remains musculoskeletal disorders. No commercial products or late-stage results are reported yet.
- Therapeutic areas
- ImmunologyRheumatology
- Modalities
- Mesenchymal stem cell therapyCell therapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on BioIntegrate.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioIntegrate.